China Biologic Completes Stock Repurchase Transaction

            China Biologic Completes Stock Repurchase Transaction

PR Newswire

BEIJING, March 3, 2014

BEIJING, March 3, 2014 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ:
CBPO, "China Biologic" or the "Company"), a leading fully integrated
plasma-based biopharmaceutical company in China, today announced that the
Company has completed its repurchase of 2.5 million shares of common stock for
a total consideration of $70 million. This transaction was originally
announced in the Company's 8-K SEC filing on January 28, 2014.

Mr. David (Xiaoying) Gao, Chairman and Chief Executive Officer of China
Biologic, commented, "In the past six months, we have closed two share
repurchase transactions totaling 3.98 million shares of common stock for a
total consideration of $99.6 million. Through these repurchase transactions,
we continue to enhance our shareholder structure and increase shareholder
value. We are also pleased that the two individual selling shareholders in
these repurchase transactions have both reached settlement with the certain
plaintiff group the title dispute regarding the Company shares held by such
selling shareholders."

As originally announced on January 28, 2014, China Biologic Products, Inc.
entered into a Repurchase Agreement with Ms. Siu Ling Chan, an individual
shareholder of the Company, and Mr. Tung Lam, the spouse of Ms. Chan, pursuant
to which the Company agreed to repurchase 2.5 million shares of its common
stock, representing approximately 9.67% of the total common stock outstanding
on January 27, 2014. The repurchase price is $28.00 per share totaling $70
million in aggregate.

About China Biologic Products, Inc.

China Biologic Products, Inc. (Nasdaq: CBPO), is a leading fully integrated
plasma-based biopharmaceutical company in China. The Company's products are
used as critical therapies during medical emergencies and for the prevention
and treatment of life-threatening diseases and immune-deficiency related
diseases. China Biologic is headquartered in Beijing and manufactures over 20
plasma-based products through its indirect majority-owned subsidiaries,
Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic
Technologies Co., Ltd. The Company also has an equity investment in Xi'an
Huitian Blood Products Co., Ltd. The Company sells its products to hospitals
and other healthcare facilities in China. For additional information, please
see the Company's website www.chinabiologic.com.

Safe Harbor Statement

This news release may contain certain "forward-looking statements" relating to
the business of China Biologic Products, Inc. and its subsidiaries. All
statements, other than statements of historical fact included herein, are
"forward-looking statements." These forward-looking statements are often
identified by the use of forward-looking terminology such as "believes,"
"expects," or similar expressions, and involve known and unknown risks and
uncertainties. Although the Company believes that the expectations reflected
in these forward-looking statements are reasonable, they involve assumptions,
risks, and uncertainties, and these expectations may prove to be incorrect.

Investors should not place undue reliance on these forward-looking statements,
which speak only as of the date of this news release. The Company's actual
results could differ materially from those anticipated in these
forward-looking statements as a result of a variety of factors, including its
potential inability to achieve the expected operating and financial
performance in 2014, potential inability to find alternative sources of
plasma, potential inability to increase production at permitted sites,
potential inability to mitigate the financial consequences of a temporarily
reduced raw plasma supply through cost cutting or other efficiencies, and
potential additional regulatory restrictions on its operations and those
additional risks and uncertainties discussed in the Company's periodic reports
that are filed with the Securities and Exchange Commission and available on
its website (http://www.sec.gov). All forward-looking statements attributable
to the Company or persons acting on its behalf are expressly qualified in
their entirety by these factors. Other than as required under the securities
laws, the Company does not assume a duty to update these forward-looking
statements.

Contact:

China Biologic Products, Inc.
Mr. Ming Yin
Vice President
Phone: +86-10-6598-3099
Email: ir@chinabiologic.com

ICR Inc.
Mr. Bill Zima
Phone: +86-10-6583-7511 or +1-646-405-5191
E-mail: bill.zima@icrinc.com

SOURCE China Biologic Products, Inc.

Website: http://www.chinabiologic.com
 
Press spacebar to pause and continue. Press esc to stop.